List of Biotech, Pharmaceutical & Life Sciences companies in Rhode Island - 14

Beech Tree Labs strives to address unmet medical needs affecting the life of millions of people. For more than 15 years, we have been developing formulations that target the body’s signals to restore a healthy equilibrium.

Blood Centers of America, Inc., (BCA) is a cooperative representing community blood centers located throughout the United States. BCA members are independent, non-profit blood centers that provide over fifty percent of the nation's transfusion requirements. For more information: http://www.bca.coop

Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.

Brown University is a higher education institution that focuses on academia and research.

Denison is a leading provider of turnkey formulation, manufacturing and packaging solutions for the branded OTC, Rx, and Cosmetic markets. Our product dosage forms include liquids, suspensions, creams, lotions, gels, and ointments. Located in Lincoln, Rhode Island, our state-of-the-art manufacturing site offers manufacturing and packaging of short, medium, and large production runs. In addition, our company maintains two sophisticated laboratories capable of providing a full suite of formulation development and analytical services.

EpiVax uses immune-engineering to develop new vaccines and to improve the immunogenicity profiles of new drugs. The company is well known for its independent thinking and interdisciplinary scientists. Thinking outside the box at EpiVax has often led to paradigm-shifting discoveries. Responsibility is another key attribute: EpiVax counts 6 of the eight largest Biotech companies in the world among its clients. EpiVax is also globally responsible: the company supports a number of not-for-profits that improve human health around the world. The company was founded in 1998 with support from the Slater Biotechnology Fund. In 2002, EpiVax was invited by the FDA to participate in one of the first ever "Immunogenicity"​ meetings. By 2006, EpiVax had developed a reputation as “thought leaders” in the field of therapeutic proteins and immunogenicity screening, providing fee-for-service solutions for first tier Pharma companies, mid to small biotech companies, and academics. The company has a solid reputation for publishing its work in academic journals (>170 publications, compared to <20 for its competitors). The EpiVax team also prides itself on delivering on promises. “We maintain a close relationship with our clients,” De Groot says. We aim to treat our clients with respect and provide capable, intelligent solutions for their needs.” The company's motto is "Fearless Science"​. For up to date news about the endeavors of our Fearless Scientists, read our blog: http://epivax.com/press/thinking-out-loud-blog

Microtissues® is a privately held company advancing technologies and applications of 3D cell culture. The company's products stand above the rest because they are designed to create more natural and more reliable 3D cell culture environments based on cell-to-cell interactions in convenient and consistent formats that generate high content information. The company's lead line of products, the 3D Petri Dish®, is serving the needs of researchers in a wide range of areas including cancer research, stem cell biology, toxicity testing, developmental biology, drug discovery, regenerative medicine and tissue engineering. In addition to products for basic research, Microtissues® is using its platform technology to pursue applications in drug discovery and cell therapy. Need more information or for a sample please email us at info@microtissues.com...

Electronic Genome Mapping Setting a new standard in structural variant analysis Nabsys, the pioneer of electronic genome mapping (EGM), uses solid-state nanodetectors to survey long DNA molecules to construct high-density maps with long-range information required to detect structural variants (SVs). Unlike other DNA mapping technologies that rely on the use of expensive optical imaging or fluorescent labels whose resolution is inherently limited by light diffraction, EGM identifies tags in close proximity therebye producing superior resolution. This high-density information makes it possible to identify both balanced and unbalanced SVs as small as 300 bp, in addition to larger chromosomal aberrations and genetic variation missed by next-generation sequencing. EGM involves simple, intuitive workflows eliminating the need for cytogenetics technical expertise, while delivering on the promise of easy-to-use, accurate, low-cost, whole-genome SV analysis. Visit the new Nabsys: https://nabsys.com/ Meet the OhmX™ Platform: Explore the genome in high-resolution. From sample prep through analysis, the OhmX end-to-end solution allows you to detect balanced and unbalanced events and a broad range of structural variants with precision. High Resolution Detection of SVs as small as 300 bp with >100 kb read lengths Low Cost Low instrument and consumable costs compared to other technologies Small Footprint Entire platform fits within 30"x17" saving valuable benchtop space Easy to Operate Easy sample prep, automated run monitoring & minimal hands-on time Accessible Analytics Web-based UI for data mining SVs via Human Chromosome Explorer™ powered by Hitachi High Tech

Ocean Biomedical is a new-generation biopharma company that partners with leading scientists and research institutions to accelerate the translation of new discoveries into breakthrough medicines. We're working to bring together the interdisciplinary expertise and resources required to develop a diverse portfolio of pharmaceutical inventions and technologies through preclinical, clinical, and commercial development. We aim to build a continuous pipeline of drug development opportunities through our relationships with universities and medical centers. Our current product candidates consist of preclinical programs each with potential for broad application in oncology, fibrosis, and the treatment and prevention of severe malaria. Our programs in oncology and fibrosis are based on discoveries of disease pathways and related drug targets emerging from pioneering work in the field of chitinase biology by our scientific co-founder, Jack A. Elias, M.D., a pulmonary specialist who was formerly the Dean of Medicine at Brown, and the Chairman of Medicine at Yale. In infectious disease, we are developing both therapeutic and vaccine candidates against malaria, a disease that kills 500,000 children and infects 200-300 million people globally each year. Our malaria program is built on the discovery by Jonathan Kurtis, M.D., of two novel malaria antigens, PfSEA-1 and PfGARP which have shown a significant reduction in malaria parasites under multiple levels of in-vitro and animal model testing. (press links below). Kurtis is the Chairman of Pathology and Laboratory Medicine at Brown and the founding director of the Center for International Health Research.

Inter-alpha Inhibitor Proteins

Signati Medical, Inc. based in Providence, Rhode Island is an early stage medical device company committed to developing its revolutionary, Sealed Vasectomy Procedure (SVP)™. Signati Medical is dedicated to advancing men's health and plans on launching its product platform in mid 2024.

TEDOR Pharma Services is a science-driven Contract, testing, Drug Development, and Manufacturing Organization (CDMO). partnering with your team to provide solutions and services for analytical testing; drug dosage development; clinical supply, packaging, distribution; and commercial manufacturing. DEA-scheduled products I-V; high potency; powder biologics; small manufacturing batches and orphan drugs for life science customers. TEDOR has helped customers meet their project timelines, achieve regulatory approvals, and solve formulation challenges. TEDOR Pharma employs skilled and specialized experts that support a wide range of capabilities that include: •Drug Product Development • Analytical Testing • Quality Assurance • Legal Compliance • Regulatory Filing • cGMP Manufacturing • Commercialization Our dynamic work environment provides a great opportunity to learn and grow professionally. We offer competitive wages and benefits, and our employees have the opportunity to drive innovative technologies, setting industry trends. TEDOR is an Equal Opportunity Employer.

Unetixs Vascular Inc. is the leading U.S.-based manufacturer of physiologic vascular instruments. We design and manufacture the country's most in-depth line of technically advanced instrumentation for diagnostic vascular testing, and we offer all our products in international markets. For over 25 years, we have listened to our customers and provided the equipment and training that best meets their needs. We rely on a team of medical professionals to provide recommendations, and we collaborate with education professionals recognized as among the best in the field to provide training. Whatever your noninvasive peripheral vascular testing requirement, you can rely on Unetixs to provide products that not only meet today's needs but can grow to fulfill tomorrow's requirements. From our portable and affordable Revo® 1100 to several MultiLab® peripheral vascular diagnostic systems, all available with our VascuLink® networking and reporting software, we have tailored a range of systems for vascular labs, hospitals, mobile services and the offices of vascular surgeons, cardiologists, primary care physicians, endocrinologists, podiatrists and other specialists.

VeroScience is committed to developing novel, practical, and effective therapies for chronic debilitating human diseases such as Type 2 diabetes, metabolic syndrome, autoimmune disease, and cancer through interdisciplinary basic research. VeroScience researchers study biological clocks in vertebrates and their organizational influence on neuroendocrine regulation of physiology to develop new treatment strategies for metabolic and immune disorders. By investigating and mimicking nature's means of regulating biochemical physiology for survival of vertebrates in the wild, VeroScience develops treatment strategies, not products per se, aimed at re-directing pathological biochemistry back towards its "normal" physiological organization. A major platform technology of the company is Circadian Neuroendocrine Resetting Therapy® that is utilized as a generator of multiple therapeutic strategies to treat a variety of disease states. The circadian timed daily (morning) administration of Cycloset®, a quick release formulation of bromocriptine mesylate (bromocriptine-QR), a dopamine agonist, was developed for the treatment of type 2 diabetes. Cycloset is approved by the U.S. FDA, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.